Literature DB >> 25398591

Effects of Traditional Chinese Medicine in Treatment of Breast Cancer Patients After Mastectomy: A Meta-Analysis.

Wei Wang1, Lin Xu2, Chaoyan Shen2.   

Abstract

The purpose of the present study is to investigate the clinical efficacy of traditional Chinese medicine (TCM) in treating breast cancer patients after mastectomy. We searched EMBASE, CENTRAL, MEDLINE, Chinese Biomedical Database, Chinese National Knowledge Infrastructure, Chinese Scientific Journal Database (VIP), and PubMed to collect randomized controlled trials of TCM in treatment of breast cancer patients after mastectomy. Quality of the methodology was assessment in accordance with Cochrane 4.2.2 Handbook. All patients were divided into two groups: TCM group (TCM only or TCM plus conventional treatment) and control group (conventional treatment only). Effects of TCM on short-term clinical outcome, long-term survival rate, and incidence of adverse reaction were compared between the two groups. Twenty-nine studies were included in this meta-analysis, involving a total of 3142 breast cancer patients. Meta-analyses showed that TCM could improve short-term treatment efficacy (Z = 7.67, RR = 1.59, 95% cl [1.41-1.80], P < 0.00001), extend 3-year (Z = 5.47, RR = 1.26, 95% cl [1.16-1.37], P < 0.00001) and 5-year (Z = 5.53, RR = 1.17, 95% cl [1.11-1.24], P < 0.00001) survival, reduce the incidence of adverse reactions in breast cancer patients after mastectomy. TCM provides beneficial and complementary effects in the treatment of breast cancer patients after mastectomy.

Entities:  

Keywords:  Breast cancer patient; Meta-analysis; Randomized controlled trial; Traditional Chinese medicine

Mesh:

Year:  2015        PMID: 25398591     DOI: 10.1007/s12013-014-0348-z

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  12 in total

1.  A systematic review and meta-analysis of traditional Chinese medicine with chemotherapy in breast cancer.

Authors:  Gang Shi; Dan Yu; Juan Wu; Yanru Liu; Ruizhen Huang; Cheng Shun Zhang
Journal:  Gland Surg       Date:  2021-05

2.  Patient-sharing relationship between Chinese medicine doctors and other physicians: costs and outcomes of breast cancer survivorship care.

Authors:  Chiu-Mei Yeh; Yiing-Jenq Chou; Shun-Ku Lin; Chia-Jen Liu; Nicole Huang
Journal:  J Cancer Surviv       Date:  2021-02-18       Impact factor: 4.442

Review 3.  Traditional Chinese medicine and cancer: History, present situation, and development.

Authors:  Jie Liu; Shuo Wang; Ying Zhang; Hui-Ting Fan; Hong-Sheng Lin
Journal:  Thorac Cancer       Date:  2015-06-16       Impact factor: 3.500

4.  Study on the Anticancer Effect of an Astragaloside- and Chlorogenic Acid-Containing Herbal Medicine (RLT-03) in Breast Cancer.

Authors:  Yanchu Li; Xianyong Li; Chen Cuiping; Rong Pu; Yin Weihua
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-10       Impact factor: 2.629

Review 5.  Meta-Analysis of Xihuang Pill Efficacy When Combined with Chemotherapy for Treatment of Breast Cancer.

Authors:  Dan Mao; Lei Feng; Siqi Huang; Shaofan Zhang; Weijun Peng; Sifang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-03-12       Impact factor: 2.629

6.  Effects of Astragaloside IV on treatment of breast cancer cells execute possibly through regulation of Nrf2 via PI3K/AKT/mTOR signaling pathway.

Authors:  Xiao-Qing Zhang; Chang Yao; Wei-He Bian; Xu Chen; Jing-Xian Xue; Zhi-Yuan Zhu; Yu Ying; Yan Lei Xu; Cong Wang
Journal:  Food Sci Nutr       Date:  2019-09-18       Impact factor: 2.863

7.  Total saponins of Bolbostemma paniculatum (maxim.) Franquet exert antitumor activity against MDA-MB-231 human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway.

Authors:  Jian-Wei Dou; Rong-Guo Shang; Xiao-Qin Lei; Kang-Le Li; Zhan-Zi Guo; Kai Ye; Xiao-Juan Yang; Yu-Wei Li; Yun-Yun Zhou; Jia Yao; Qian Huang
Journal:  BMC Complement Altern Med       Date:  2019-11-08       Impact factor: 3.659

8.  XIAOPI Formula Inhibits Breast Cancer Stem Cells via Suppressing Tumor-Associated Macrophages/C-X-C Motif Chemokine Ligand 1 Pathway.

Authors:  Shengqi Wang; Xiaoyan Liu; Renlun Huang; Yifeng Zheng; Neng Wang; Bowen Yang; Honglin Situ; Yi Lin; Zhiyu Wang
Journal:  Front Pharmacol       Date:  2019-11-15       Impact factor: 5.810

9.  Chemotherapy in conjunction with traditional Chinese medicine for survival of patients with early female breast cancer: protocol for a non-randomized, single center prospective cohort study.

Authors:  Chien-Ting Liu; Yen-Hao Chen; Yu-Chuen Huang; Shih-Yu Chen; Ming-Yen Tsai
Journal:  Trials       Date:  2019-12-17       Impact factor: 2.279

10.  Guizhi Fuling Decoction inhibiting the PI3K and MAPK pathways in breast cancer cells revealed by HTS2 technology and systems pharmacology.

Authors:  Yifei Dai; Weijie Qiang; Xiankuo Yu; Siwei Cai; Kequan Lin; Lan Xie; Xun Lan; Dong Wang
Journal:  Comput Struct Biotechnol J       Date:  2020-05-18       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.